Overview

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
To investigate the safety and efficacy of letrozole monotherapy at a dose of 2.5 mg/day in postmenopausal patients with breast cancer, and to determine the blood concentrations of letrozole and hormones.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Collaborator:
Chugai Pharmaceutical
Treatments:
Letrozole